Cargando…
The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001641/ https://www.ncbi.nlm.nih.gov/pubmed/35410412 http://dx.doi.org/10.1038/s41408-022-00664-y |
| _version_ | 1784685718691381248 |
|---|---|
| author | Lim, Byungho Yoo, Dabin Chun, Younghwa Go, Areum Cho, Kyung-Jin Choi, Daeun Jung, Myoung Eun Lee, Ha Young Boohaker, Rebecca J. Lee, Jin Soo Jung, DooYoung Choi, Gildon |
| author_facet | Lim, Byungho Yoo, Dabin Chun, Younghwa Go, Areum Cho, Kyung-Jin Choi, Daeun Jung, Myoung Eun Lee, Ha Young Boohaker, Rebecca J. Lee, Jin Soo Jung, DooYoung Choi, Gildon |
| author_sort | Lim, Byungho |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9001641 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Nature Publishing Group UK |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-90016412022-04-27 The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia Lim, Byungho Yoo, Dabin Chun, Younghwa Go, Areum Cho, Kyung-Jin Choi, Daeun Jung, Myoung Eun Lee, Ha Young Boohaker, Rebecca J. Lee, Jin Soo Jung, DooYoung Choi, Gildon Blood Cancer J Correspondence Nature Publishing Group UK 2022-04-11 /pmc/articles/PMC9001641/ /pubmed/35410412 http://dx.doi.org/10.1038/s41408-022-00664-y Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
| spellingShingle | Correspondence Lim, Byungho Yoo, Dabin Chun, Younghwa Go, Areum Cho, Kyung-Jin Choi, Daeun Jung, Myoung Eun Lee, Ha Young Boohaker, Rebecca J. Lee, Jin Soo Jung, DooYoung Choi, Gildon The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia |
| title | The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia |
| title_full | The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia |
| title_fullStr | The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia |
| title_full_unstemmed | The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia |
| title_short | The preclinical efficacy of the novel hypomethylating agent NTX-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia |
| title_sort | preclinical efficacy of the novel hypomethylating agent ntx-301 as a monotherapy and in combination with venetoclax in acute myeloid leukemia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9001641/ https://www.ncbi.nlm.nih.gov/pubmed/35410412 http://dx.doi.org/10.1038/s41408-022-00664-y |
| work_keys_str_mv | AT limbyungho thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT yoodabin thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT chunyounghwa thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT goareum thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT chokyungjin thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT choidaeun thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT jungmyoungeun thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT leehayoung thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT boohakerrebeccaj thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT leejinsoo thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT jungdooyoung thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT choigildon thepreclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT limbyungho preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT yoodabin preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT chunyounghwa preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT goareum preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT chokyungjin preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT choidaeun preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT jungmyoungeun preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT leehayoung preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT boohakerrebeccaj preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT leejinsoo preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT jungdooyoung preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia AT choigildon preclinicalefficacyofthenovelhypomethylatingagentntx301asamonotherapyandincombinationwithvenetoclaxinacutemyeloidleukemia |